Skip to main content
Premium Trial:

Request an Annual Quote

Illumina's Q3 Revenue Surges 82 Percent on Strong Product Sales, Though Profit Slides

NEW YORK (GenomeWeb News) — Illumina yesterday said third-quarter revenues bolted 82 percent and R&D spending rose 160 percent, though profits fell 10 percent.
Total receipts for the three months ended Sept. 30 increased to $97.5 million from $53.5 million year over year.
Product revenues leapt to $90 million from $46.9 million, while service and other revenue rose to $7.4 million from $6.4 million year over year.
R&D spending increased to $19.8 million from $7.7 million in the year-ago period, including around $13.2 million in non-cash stock compensation expenses.
Profit for the quarter declined to $14.5 million from $16.2 million.
Illumina said it had around $352.8 million in cash, equivalents, and short-term investments as of Sept. 30.
The company raised its expected full-year 2007 revenue to between $354 million and $358 million, which is $16 million higher than projections it made in July, or around 17 percent more than it projected at the beginning of the year.
Illumina expects fourth-quarter revenue to be between $100 million and $104 million, or as much as 69 percent over the same period last year.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.